They assess the extensive evidence on the mechanisms by which REDD1 acts as a detrimental factor in serious conditions, including metabolic disorders, cancer, muscle atrophy, neurological diseases, and autoimmune diseases. This evidence concerns the gene DDIT4 and Other metabolic disease.